Targeted therapies in non-small cell lung cancer

Cancer Imaging

Volumn 8, Issue 1, 2008, Pages 199-205

  Kyle, Fiona ^a   Spicer, James ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Non small cell lung cancer; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; VASCULOTROPIN A;

ARTICLE; DRUG EFFECT; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MORTALITY; PATHOLOGY; PHYSIOLOGY; SURVIVAL; SURVIVOR;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; SURVIVORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65849197346     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2008.0027     Document Type: Review

References (45)

1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2004; 346: 92-8.
2. Shepherd FA, Dancey J, Ramlay R, et al Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinumbased chemotherapy. J Clin Oncol 2000; 18: 2095-103. (Pubitemid 30324363)
3. Hanna N, Shepherd FA, Fossela FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with nonsmall-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-97. (Pubitemid 41079796)
4. Shepherd F, Pereira J, Cluleanu TE, et al. A randomized placebocontrolled trial of erlotinib in patients with advanced non-small cell lung cancer following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group trial. J Clin Oncol 2004; 22( 14S): 7022.
5. Fukuoka M, Yanos S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-46. (Pubitemid 46621858)
6. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-58. (Pubitemid 37432975)
7. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-37. (Pubitemid 41540110)
8. Douillard J-Y, Kim E, Hirsh V. Gefitinib (Iressa) versus docetaxel in patients with locally advanced or metastatic NSCLC pre-treated with platinum based chemotherapy: A randomised open label phase III study (Interest). J Thorac Oncol 2007; 2: S305-6.
9. Lynch TJ, Bell D, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39. (Pubitemid 38637993)
10. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500. (Pubitemid 38720929)
11. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-11. (Pubitemid 39209661)
12. Shigematsu H, Takahashi T, Nomura M, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-46. (Pubitemid 40425952)
13. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced nonsmall-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006; 24: 3340-6. (Pubitemid 46638887)
14. Paz-Ares L, Sanchez M, Garcia-Valasco B, et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer patients with mutations in the tyrosine kinase domain of the epidermal growth factor receptor. J Clin Oncol 2006; 24( 18S): 7020a.
15. Okamoto I, Kashii T, Urata Y, et al. EGFR mutation-based phase II multicenter trial of gefitinib in advanced non-small cell lung cancer patients: results of West Japan thoracic oncology group trial (WJTOG0403). J Clin Oncol 2006; 24( 18S): 7073a.
16. Sutani A, Nagai Y, Udagawa K, et al. Phase II study of gefitinib for non-small cell lung cancer patients with epidermal growth factor receptor gene mutations detected by PNA-LNA PCR clamp. J Clin Oncol 2006; 24( 18S): 7076a.
17. Morikawa N, Inoue A, Sukaki T, et al. Prospective analysis of the epidermal growth factor receptor gene mutations in non-small cell lung cancer in Japan. J Clin Oncol 2006; 24( 18S): 7077.
18. Sequist L, Martins RG, Spigel D, et al. iARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor-mutated non-small cell lung cancer tumors. J Clin Oncol 2007; 25( 18S): 7504.
19. Herbst R, Prager D, Hermann R, et al. Tribute - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004; 22( 14S): 7011.
20. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25: 1545-52. (Pubitemid 46733081)
21. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22: 777-84. (Pubitemid 41103588)
22. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial -INTACT 2. J Clin Oncol 2004; 22: 785-94. (Pubitemid 41103589)
23. Jackman DM, Yeap YB, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007; 25: 760-6. (Pubitemid 350002874)
24. Lilenbaum R, Axerold R, Thomas S, et al. Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer and performance status of 2. J Clin Oncol 2006; 24( 18S): 7022a.
25. Crino L, Zatloukal P, Reck M, et al. Gefitinib versus vinorelbine in chemonaive elderly patients with advanced NSCLC (INVITE): A randomised phase II study B3-04. J Thor Oncol 2007; 2( 8): S341.
26. Kelly K, Chansky K, Gaspar LE, et al. Updated analysis of SWOG 0023: A randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer. J Clin Oncol 2007; 25( 18S): 7513A.
27. Kobayashi S, Boggon T, Dayaram R, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-92. (Pubitemid 40271173)
28. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
29. Hanna N, Bonomi P, Lynch T. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). Lung Cancer 2005; 49( Suppl. 3): S38.
30. Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFRexpressing advanced non-small-cell lung cancer. Ann Oncol, 2007; 19: 362-9.
31. Butts CA, Bodkin D, Middleman E, et al. Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007; 25: 5777-84.
32. Lynch T, Patel T, Dreisbach L, et al. A randomized multicenter phase III study of cetuximab in combination with Taxane/ Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer: B3-03. J Thorac Oncol 2007; 2: 340.
33. Hirsch FR, Langer CJ. The role of HER2/neu expression and trastuzumab in non-small cell lung cancer. Semin Oncol 2004; 31(1 Suppl 1): 75-82. (Pubitemid 38241024)
34. Stephens P, Hunter C, Bignell G, et al. Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 2004; 431: 525-6.
35. Sandler A, Gray R, Perry M, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50. (Pubitemid 44917502)
36. Manegold C, von Pawel J, Zatioukal P, et al. Randomised, doubleblind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer: BO17704. J Clin Oncol 2007; 25( 18S): 7514.
37. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-91. (Pubitemid 41095154)
38. Herbst RS, Johnson DH, Minnenberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 2544-55.
39. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebocontrolled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007; 25: 4270-7. (Pubitemid 47548567)
40. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84. (Pubitemid 41464706)
41. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst 2000; 92: 205-16.
42. Michaelis LC, Ratain MJ. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 2006; 6: 409-14.
43. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006; 24: 3282-92. (Pubitemid 46622068)
44. Brindle K. New approaches for imaging tumour responses to treatment. Nat Rev Cancer 2008; 8: 94-107. (Pubitemid 351161320)
45. Smit E, Egbert F, Hoestra C. New imaging techniques for lung cancer staging and response assessment. J Thorac Oncol 2007; 2: S144-5.